Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) FCF Margin (2016 - 2024)

Historic FCF Margin for Summit Therapeutics (SMMT) over the last 7 years, with Q2 2024 value amounting to 1065.93%.

  • Summit Therapeutics' FCF Margin changed N/A to 1065.93% in Q2 2024 from the same period last year, while for Sep 2025 it was 1.45047488036864e19%, marking a year-over-year decrease of 1.4504748803686405e23%. This contributed to the annual value of 5986.67% for FY2022, which is 19572000.0% down from last year.
  • Summit Therapeutics' FCF Margin amounted to 1065.93% in Q2 2024.
  • In the past 5 years, Summit Therapeutics' FCF Margin ranged from a high of 2639.53% in Q1 2020 and a low of 3879.55% during Q3 2022
  • Its 3-year average for FCF Margin is 197.89%, with a median of 1015.79% in 2024.
  • The largest annual percentage gain for Summit Therapeutics' FCF Margin in the last 5 years was 4963300bps (2020), contrasted with its biggest fall of 4963300bps (2020).
  • Summit Therapeutics' FCF Margin (Quarter) stood at 2639.53% in 2020, then crashed by -247bps to 3879.55% in 2022, then soared by 127bps to 1065.93% in 2024.
  • Its last three reported values are 1065.93% in Q2 2024, 965.65% for Q1 2024, and 3879.55% during Q3 2022.